Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by analysts at BTIG Research from a “neutral” rating to a “sell” rating in a research note issued to investors on Friday. They currently have a $17.00 target price on the stock. BTIG Research’s target price would indicate a potential downside of 19.74% from the company’s current price.
Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Friday. Piper Jaffray Companies set a $16.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, December 14th. Cantor Fitzgerald set a $18.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Wednesday, January 3rd. Royal Bank of Canada lifted their price objective on shares of Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the company an “underperform” rating in a research note on Sunday, November 5th. Finally, Leerink Swann began coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, January 2nd. They issued an “underperform” rating and a $15.00 price objective for the company. Nine investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and an average target price of $21.54.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $21.18 on Friday. The stock has a market cap of $20,736.56 and a price-to-earnings ratio of -3.56. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $37.94. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.
Several large investors have recently bought and sold shares of the company. Northern Cross LLC increased its holdings in shares of Teva Pharmaceutical Industries by 14.0% during the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after purchasing an additional 2,184,172 shares during the period. Schroder Investment Management Group increased its holdings in shares of Teva Pharmaceutical Industries by 22.7% during the 3rd quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock worth $106,290,000 after purchasing an additional 1,147,683 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 4.5% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock worth $106,271,000 after purchasing an additional 259,891 shares during the period. State Street Corp increased its holdings in shares of Teva Pharmaceutical Industries by 5.1% during the 2nd quarter. State Street Corp now owns 4,763,692 shares of the company’s stock worth $158,254,000 after purchasing an additional 232,924 shares during the period. Finally, Macquarie Group Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 350.3% during the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after purchasing an additional 3,429,448 shares during the period. Institutional investors own 51.88% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking and Market News and is the sole property of of American Banking and Market News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/02/teva-pharmaceutical-industries-teva-downgraded-by-btig-research-to-sell.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
